



Durham Region Health Department FAX about...

For Health Care Professionals



Men-C-ACYW-135 Product Update: MenQuadfi™

MenQuadfi™, a publicly funded **Men-C-ACYW-135 vaccine** will be available soon. It is comparable to other publicly funded meningococcal conjugate vaccines, Menactra® and Nimenrix®, with the following age indications:

- **Menactra® and Nimenrix®**: authorized and publicly funded for individuals **9 months of age and older**
- **MenQuadfi™**: authorized and publicly funded for individuals **12 months of age and older**


In the coming weeks, vaccine orders for Men-C-ACYW-135 may include MenQuadfi™.

MenQuadfi™ is indicated for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W and Y. It is considered **equivalent** to other publicly funded Men-C-ACYW-135 vaccines and may be used within both the **routine and high-risk immunization programs** for individuals **12 months of age and older**. There are **no changes to eligibility criteria** as a result of this product introduction.

Any existing inventory of Menactra® and Nimenrix® may continue to be used until expiry. As per standard vaccine storage and handling practices, Men-C-ACYW-135 vaccine products with the **nearest expiry date should be used first**.

MenQuadfi™ Packaging

- Supplied as a 0.5 ml single-dose vial.
- Packaging contains 10 single-dose vials.
- Package dimensions: 1.77" x 2.28" x 1.25".



For additional product information, please refer to the MenQuadfi™ Product Monograph:

sanofi.com/assets/countries/canada/docs/products/vaccines/menquadfi-en.pdf.

Visit durham.ca/hcp (select FORMS, then ORDER) for the most up-to-date vaccine order forms.

January 26, 2026

905-668-2020 or 1-800-841-2729 | durham.ca/health

If you require this information in an accessible format, contact 1-800-841-2729.

